Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytoxicity

Nature Immunology

Volumn 2, Issue 4, 2001, Pages 333-337

  Aoki, Kazunori ^a,c   Kurooka, Masayuki ^a   Chen, Jian Jun ^a   Petryniak, Jerzy ^a   Nabel, Elizabeth G ^b   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; FASL PROTEIN, MOUSE; FASLG PROTEIN, HUMAN; LIGAND; MEMBRANE PROTEIN; PRIMER DNA;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; CHEMISTRY; CYTOTOXICITY; EXTRACELLULAR MATRIX; EYE; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; SOLUBILITY; TESTIS;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; EXTRACELLULAR MATRIX; EYE; FAS LIGAND PROTEIN; HUMANS; IMMUNE TOLERANCE; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MUTAGENESIS, SITE-DIRECTED; SIGNAL TRANSDUCTION; SOLUBILITY; TESTIS;

EID: 0035318305     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/86336     Document Type: Article

References (32)

1. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991).
2. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand. a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
3. Brunner, T. et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444 (1995).
4. Dhein, J., Walczak, H., Baumler, C., Debatin, K.-M. & Krammer, P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441 (1995).
5. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995).
6. Ju, S. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448 (1995).
7. Arai, H., Chan, S. Y., Bishop, D. K. & Nabel, G. J. Inhibition of the alloantibody response by CD95 ligand. Nature Med. 3, 843-648 (1997).
8. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R. & Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
9. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
10. Strand, S. et al. Lymphocyte apoptosis induced by CD95/(APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 2, 1361-1366 (1996).
11. Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366 (1996).
12. Lau, H. T., Yu, M., Fontana, A. & Stoeckert, C. J. Jr Prevention of islet ollograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
13. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135 (1995).
14. Kayagaki, N. et al. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182, 1777-1783 (1995).
15. Tanaka, M., Itai, T. Adachi, M. & Nagata, S. Down regulation of Fas ligand by shedding. Nature Med. 4, 31-36 (1998).
16. Schneider, P. et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187, 1205-1213 (1998).
17. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317-322 (1996).
18. Rensing-Ehl, A. et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258 (1995).
19. Tanaka, M., Suda, T., Yatomi, T., Nakamura, N. & Nagata, S. Lethal effect of recombinant human Fas ligand in mice pretreated with propionibacterium acnes. J. Immunology 158, 2303-2309 (1997).
20. Peitsch, M. C. & Tschopp, J. Comparative molecular modelling of the Fas-ligand and other members of the TNF family. Mol. Immunol. 32, 761-772 (1995).
21. Schneider, P. et al. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 272, 18827-18833 (1997).
22. Declerck, P. J. et al. Purification and characterization of a plasminogen activator inhibitor I binding protein from human plasma. J. Biol. Chem. 263, 15454-15461 (1988).
23. Lawrence, D., Strandberg, L., Grundstrom, T. & Ny, T. Purification of active human plasminogen activator inhibitor 1 from E. coli. Eur. J. Biochem. 186, 523-533 (1989).
24. Zheng, X., Saunders, T. L., Camper, S. A., Samuelson, L. C. & Ginsburg, D. Vitronectin is not essential for normal mammalian development and fertility. Proc. Natl Acad. Sci. USA 92, 12426-12430 (1995).
25. Erickson, L. A. et al. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346, 74-76 (1990).
26. Carmetiet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. J. Clin. Invest. 92, 2746-2755 (1993).
27. Salonen, E. et al. Interaction of Plasminogen activator inhibitor (PAI-1) with vitronectin. J. Biol. Chem. 264, 6339-6343 (1989).
28. Seiffert, D., Wagner, N. & Loskutoff, D. Serum-derived vitronectin influences the pericellular distribution of type I plasminogen activator inhibitor. J. Cell Biol. 111, 1283-1291 (1990).
29. Chen, J.-J., Sun, Y. & Nabel, G. J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717 (1998).
30. Dick, A. D. et al. Fas-Fas Ligand-Mediated Apoptosis within Aqueous during Idiopathic Acute Anterior Uveitis. Invest. Ophthalmol. Vis. Sci. 40, 2258-2267 (1999).
31. Sotozono, C. et al. Soluble Fas ligand expression in the ocular fluids of uveitis patients. Curr. Eye Res. 20, 54-57 (2000).
32. Kayagaki, N. et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl Acad. Sci. USA 94, 5986-5990 (1997).